ACXP vs. INDP, AYTU, GTHX, RGLS, SCPH, MCRB, HOWL, IMAB, RAPT, and SYRS
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Indaptus Therapeutics (INDP), Aytu BioPharma (AYTU), G1 Therapeutics (GTHX), Regulus Therapeutics (RGLS), scPharmaceuticals (SCPH), Seres Therapeutics (MCRB), Werewolf Therapeutics (HOWL), I-Mab (IMAB), RAPT Therapeutics (RAPT), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical preparations" industry.
Acurx Pharmaceuticals (NASDAQ:ACXP) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
Acurx Pharmaceuticals presently has a consensus price target of $12.00, indicating a potential upside of 400.00%. Indaptus Therapeutics has a consensus price target of $12.00, indicating a potential upside of 352.83%. Given Acurx Pharmaceuticals' higher probable upside, equities research analysts plainly believe Acurx Pharmaceuticals is more favorable than Indaptus Therapeutics.
Acurx Pharmaceuticals received 1 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. Likewise, 91.67% of users gave Acurx Pharmaceuticals an outperform vote while only 83.33% of users gave Indaptus Therapeutics an outperform vote.
Indaptus Therapeutics' return on equity of -108.14% beat Acurx Pharmaceuticals' return on equity.
In the previous week, Acurx Pharmaceuticals' average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.
Acurx Pharmaceuticals has a beta of -1.7, suggesting that its stock price is 270% less volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.
11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 35.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 29.5% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Acurx Pharmaceuticals beats Indaptus Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Acurx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
